NCT06960954

PIVKA-II for Predicting Portal Vein Thrombosis in Hepatocellular Carcinoma

Prothrombin Induced by Vitamin K Absence II (PIVKA-II) Serum Level as a Predictor for Portal Vein Tumor Thrombosis in Hepatocellular Carcinoma Patients.

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 116 (estimated)
• Sponsor: Tanta University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this cross-sectional observational study is to evaluate the relation between Prothrombin induced by vitamin K absence II (PIVKA-II) and the presence of portal vein tumor thrombosis (PVTT) in hepatocellular carcinoma (HCC) patients. Researchers will compare PIVKA-II serum levels in HCC patients with PVTT and without PVTT. Participants will undergo history-taking, clinical examination, laboratory investigations, PIVKA-II serum level, Child-Pugh classification, Model for End-stage Liver Disease (MELD) score, BCLC staging, abdominal ultrasonography, and Triphasic CT abdomen with contrast or MRI to evaluate tumor site, size, number, and presence of PVTT (a filling defect in the portal vein or its branch to distinguish PVTT or thrombus).

Conditions

• Hepato Cellular Carcinoma (HCC)
• Portal Vein Tumour Thrombosis

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	Prothrombin induced by vitamin K absence II (PIVKA-II)	Serum PIVKA-II level will be measured in HCC patients with and without PVTT.

Timeline

• Start date: 2025-01-15
• Primary completion: 2025-12-15
• Completion: 2025-12-31
• First posted: 2025-05-07
• Last updated: 2025-05-07

Locations

1 site across 1 country: Egypt